SCI-110's advancement into a Phase IIb trial for Tourette syndrome is a high-risk venture, predicated on an efficacy signal that falls substantially short of established cannabinoid approval benchmarks. [1] The reported 21% average tic reduction from the Phase IIa study provides a proof-of-concept but is modest compared to the pivotal trial data for Epidiolex, the key cannabinoid precedent. Epidiolex gained approval for Lennox-Gastaut syndrome (LGS) based on a 44% median seizure reduction, setting a high bar for what regulators consider clinically meaningful. SCI-110 also targets an indication with only a Grade C (weak) evidence base for cannabinoids, unlike the more robust evidence supporting epilepsy approvals. [2] Competitors like approved antipsychotics and behavioral interventions represent an established standard of care. Furthermore, the commercial path is challenged by unfavorable cost-effectiveness precedents, such as Epidiolex's $451,800 per QALY ICER in LGS, which is far above typical payer willingness-to-pay thresholds. [3] Without data showing a substantial improvement over the Phase IIa signal, a clear safety advantage over generic antipsychotics, or a compelling quality-of-life benefit, SCI-110 faces significant hurdles to regulatory approval and market access.
The 21% average tic reduction is substantially lower than efficacy demonstrated in pivotal trials for approved cannabinoid therapies (e.g., 44% in LGS). [3] The asset also targets an indication with only a Grade C (weak) evidence base for cannabinoids.
| Indication | Tourette Syndrome |
| Drug | SCI-110 |
| Mechanism of Action | Cannabinoid-based treatment |
| Company | SciSparc Ltd. |
| Trial Phase | Phase IIb |
| Category | Clinical Trial Event |
| Sub Category | Trial Initiation / First Patient In (FPI) |
| Therapeutic Area | Neuroscience |
| Clinical Trial Sites | Hannover Medical School, Yale Child Study Center, Tel Aviv Sourasky Medical Center |
| Regulatory Clearances | Germany’s Federal Institute for Drugs and Medical Devices, MHH's ethics committee |
| Patient Age Range | 18-65 |
| Primary Efficacy Endpoint | change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline |
| Trial Type | randomized, double-blind, placebo-controlled, cross-over trial |
| Previous Phase IIa Results | average tic reduction of 21% on Yale Global Tic Severity Scale Total Tic Score |
| Drug Components | dronabinol, palmitoylethanolamide |
| Measurement Scale | Yale Global Tic Severity Scale |
NeuroThera Labs Initiates Phase IIb Trial for Tourette Syndrome Treatment
SciSparc Ltd., through its subsidiary NeuroThera Labs Inc., has announced the initiation of a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults. This trial, which previously received regulatory clearance, aims to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Building on positive Phase IIa results that showed an average tic reduction of 21%, the randomized, double-blind, placebo-controlled, cross-over study will assess changes in tic severity using the Yale Global Tic Severity Scale. The trial will also be conducted at Yale Child Study Center and Tel Aviv Sourasky Medical Center.
- The Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110 in adults aged 18-65 with Tourette Syndrome. The primary efficacy endpoint is the change in tic severity, measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline, with safety assessed through adverse event monitoring.
- SCI-110 is an innovative one-dosage form combining dronabinol, a synthetic cannabinoid, with the endocannabinoid-like palmitoylethanolamide. This proprietary cannabinoid-based treatment candidate is designed to reduce tics and comorbid symptoms in adults with TS while minimizing potential side effects, addressing a significant unmet medical need.
- The initiation of the German site at Hannover Medical School marks a key step in the global development program for SCI-110, with additional sites planned at Yale Child Study Center in Connecticut and Tel Aviv Sourasky Medical Center in Israel. This advancement follows positive safety and efficacy results from a preceding Phase IIa study, which demonstrated an average tic reduction of 21% across participants.
Current Limitations in Tourette Syndrome Treatment Approaches
Current management strategies for Tourette Syndrome—spanning behavioral therapy, pharmacotherapy, and emerging interventions—remain constrained by incomplete efficacy, side-effect burdens, and accessibility barriers. A substantial subset of patients continues to experience clinically significant, functionally impairing tics despite adequate trials of first-line approaches, underscoring persistent gaps in the treatment landscape.
Partial efficacy and realistic goals: Evidence-based treatments (behavior therapy and pharmacotherapy) are often only partially effective and are geared toward reducing tic severity to a functionally manageable level rather than achieving symptom elimination; many patients also face accessibility barriers to these interventions.
Treatment-resistant population: A significant proportion of patients remain refractory, defined as persistent, functionally impairing tics despite adequate behavioral therapy and trials of at least two pharmacological agents from different classes at appropriate doses and durations.
Weak evidentiary foundation for guidelines: Current treatment guidelines rely heavily on limited clinical trials and expert opinion, with dopamine-modulating agents and alpha-2 agonists as the most commonly used pharmacological options; real-world effectiveness and generalizability of these agents remain open questions requiring further study.
Heterogeneous evidence for alternative interventions: Options for treatment-resistant TS—including cannabinoid-based treatments—are supported by inconsistent, often non-statistically significant results derived largely from small or uncontrolled studies. Non-pharmacological alternative approaches are similarly limited, with evidence largely anecdotal or case-based.
Cannabinoid-related safety concerns: Medical cannabis has been associated with cognitive side effects (in ~40% of patients), including altered time perception, visuospatial disorientation, confusion, slowed processing speed, and attention difficulties, as well as psychiatric side effects such as worsening OCD symptoms, panic attacks, and anxiety.
Complementary and alternative medicine (CAM) knowledge gaps: Robust data on CAM efficacy and safety in TS specifically are lacking, with few dedicated studies. Compounding this, patients frequently do not disclose CAM use to physicians unless directly asked, limiting clinical oversight and data collection.
Provider unfamiliarity with behavioral techniques: Many clinicians remain unfamiliar with habit reversal training, potentially limiting appropriate referral and implementation of this evidence-based behavioral approach.
Device-based therapy limitations: While Deep Brain Stimulation (DBS) shows superior efficacy and lower complication rates compared to pharmacotherapy and psychotherapy in medically intractable TS, the optimal neural target for stimulation remains undefined, despite several targets showing symptom benefit.
Emerging and adjunct therapies still under investigation: Novel approaches such as remotely delivered mindfulness-based interventions, immunomodulatory therapy, and botulinum toxin are being explored to diversify the treatment armamentarium, but their comparative efficacy, mechanisms, and durability of benefit are not yet fully established.
Frequently Asked Questions
References
- [1] Dooley JM. Tic disorders in childhood. Seminars in pediatric neurology. 2006 Dec. 17178353
- [2] Himle MB, Woods DW et al.. Brief review of habit reversal training for Tourette syndrome. Journal of child neurology. 2006 Aug. 16970874
- [3] Cavanna AE. When is pharmacotherapy necessary for Tourette syndrome? The risks vs reward. Expert opinion on pharmacotherapy. 2026 Jan. 41653044
- [4] Tomskiy AA, Poddubskaya AA et al.. Neurosurgical management of Tourette syndrome: A literature review and analysis of a case series treated with deep brain stimulation. Progress in brain research. 2022. 35667806
- [5] Singer HS. The treatment of tics. Current neurology and neuroscience reports. 2001 Mar. 11898516
- [6] Hartmann A, Martino D et al.. Gilles de la Tourette syndrome - A treatable condition?. Revue neurologique. 2016 Aug-Sep. 27476415
- [7] Farhat LC, Behling E et al.. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. The Lancet. Child & adolescent health. 2023 Feb. 36528030
- [8] Cavanna AE, Termine C. Tourette syndrome. Advances in experimental medicine and biology. 2012. 22411257
- [9] Dutta N, Cavanna AE. The effectiveness of habit reversal therapy in the treatment of Tourette syndrome and other chronic tic disorders: a systematic review. Functional neurology. 2013 Jan-Mar. 23731910
- [10] Mahajan UV, Purger DA et al.. Deep Brain Stimulation Results in Greater Symptomatic Improvement in Tourette Syndrome than Conservative Measures: A Meta-Analysis. Stereotactic and functional neurosurgery. 2020. 32434201
- [11] Anis S, Zalomek C et al.. Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study. Behavioural neurology. 2022. 35310886
- [12] Reese HE, Brown WA et al.. Remote delivery of a mindfulness-based intervention for adults with tics: Protocol of a randomized controlled trial. Contemporary clinical trials. 2026 Mar. 41539536
- [13] Morand-Beaulieu S, Leclerc JB. [Tourette syndrome: Research challenges to improve clinical practice]. L'Encephale. 2020 Apr. 32014239
- [14] Kumar A, Duda L et al.. A Comprehensive Review of Tourette Syndrome and Complementary Alternative Medicine. Current developmental disorders reports. 2018. 29755921
- [15] Badenoch J, Cavanna AE. Pharmacotherapy for tics in adult patients with Tourette syndrome and other tic disorders. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2020 Jul. 32170503
- [16] Czech A, Czarnecka M et al.. Alternative Treatment of the Resistant-to-Treatment Tourette Syndrome-A Systematic Review. Journal of clinical medicine. 2026 Apr 29. 42123126
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
